Sava Technologies

FDA-cleared over-the-counter continuous glucose sensors are expanding glucose monitoring beyond insulin users, but evidence for meaningful weight loss or broad metabolic benefits in people without diabetes remains limited. Representative image.

Medical Devices & Diagnostics

Could a sensor 10 times shorter challenge Dexcom and Abbott? Ascensia is betting on Sava

by Pallavi Madhiraju
October 11, 2026
0 Comments

Ascensia backs Sava's $36M glucose microsensor push, but clinical validation and CE marking remain critical before its planned European launch.

Read More